

- Amsterdam
74. Okusaka T, Furuse J, Gemma A, Hatori T, Ichikawa W, Seki A: Safety profile of erlotinib in a Japanese post-marketing surveillance study of pancreatic cancer patients (pts): Interim analysis of the first 313 pts of 855 pts enrolled. The European Cancer Congress 2013. abstr 2615, 2013.9.30, Amsterdam
 75. Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J: Salvage chemotherapy of fixed dose rate gemcitabine and S-1 combination therapy (FGS) for gemcitabine-refractory advanced pancreatic cancer. The European Cancer Congress 2013. abstr 2641. 2013.9.30, Amsterdam
 76. T. Okusaka, M. Ueno, Y. Omuro, H. Isayama, A. Fukutomi, M. Ikeda, A. Fukutomi, K. Fukuzawa, I. Hyodo, N. Boku. Randomized phase II study comparing S-1 plus Leucovorin(SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC). 17th ECCO-38thESMO-32nd ESTRO European Cancer Congress 27 September-1October Amsterdam 2013
 77. H. Ueno, T. Ioka, S. Ohkawa, M. Ikeda, T. Shimamura, A. Tsuji, Y. Tsuchiya, T. Okusaka T, Yoshida, Y. Sato. SLCO1B1 gene single nucleotide polymorphism is a drug response marker-for pancreatic cancer patients treated with gemcitabine. 17th ECCO-38thESMO-32nd ESTRO European Cancer Congress 27 September-1October Amsterdam.2013
 78. 佐々木満仁、濱口哲弥、森実千種、後藤慶子、山田康秀、島田安博、近藤俊輔、上野秀樹、奥坂拓志、谷口浩和、平岡伸介、久嶋亮治。肝転移を有する切除不能消化器神経内分泌腫瘍に対する内科的治療の検討。(ポスターセッション 2) 膵・遠隔転移治療 P2-5) 第1回日本神経内分泌腫瘍研究会学術集会。2013.9.28日。於：京都市
 79. 上杉和寛、松本俊彦、浅木彰則、灘野成人、井口東郎。膵神経内分泌腫瘍に対する核医学治療 (PRRT) :症例報告。第1回日本神経内分泌腫瘍研究会学術集会 2013.9.28日、京都。
 80. 五十嵐久人、伊藤鉄英。シンポジウム、肝転移を有する神経内分泌腫瘍の治療方針第1回 日本神経内分泌腫瘍研究会学術集会 2013.9.28 京都
 81. 植田圭二郎、新名雄介、肱岡真之、李倫學、立花雄一、三木正美、藤山 隆、内田匡彦、五十嵐久人、相島慎一、田中雅夫、伊藤鉄英。神経内分泌腫瘍と十二指腸 GIST が合併した1症例。第1回 日本神経内分泌腫瘍研究会学術集会 2013.9.28 京都
 82. 山内 浩史、木田光広、三島 孝仁、徳永 周子、奥脇 興介、宮澤 志朗、岩井知久、竹澤 三代子、菊地 秀彦、渡辺摩也、今泉 弘、小泉 和三郎: 術後再建腸管に対する Short type Single Balloon Enteroscope(SBE) を用いた ERCP の使用経験と従来型との比較、第 49 回日本胆道学会学術集会、2013.9.19, 千葉, 胆道, 27 巻 3 号 Page470(2013.08).
 83. 桑原明子、池田公史、奥山浩之、高橋秀明、大野泉、清水怜、光永修一、本多正幸、小西大、小嶋基寛。エルロチニブ併用ゲムシタピン療法が奏効し切除可能となった進行膵癌の一例 日本消化器病学会 関東支部第 326 回例会 2013.09.14 東京
 84. 木田光広: EUS, EUS-FNA for Upper GI, 第 11 回 Mumbai Endoscopy Live, 2013.9.6, インド・ムンバイ
 85. Nobumasa Mizuno, Yoshikuni Nagashio, Kenji Yamao. Diagnostic performance of cyst fluid analysis and cytology in pancreatic cystic lesions. Symposium IX: Controversies in Clinical Pancreatology I: Pancreatic Cystic Disease. Joint Meeting of the International Association of Pancreatology and the Korean Pancreatobiliary Association 2013, Seoul, Kore, September 2013.
 86. 木田光広: 治療現場最前線 北里大学医学部消化器内科学 (胆膵グループ), 膵・胆道癌, FRONTIER, 2013.9, 3(2):24-27.
 87. 古瀬純司:膵がん化学療法 of 最新情報ーガイドライン改訂を踏まえて。モーニングセミナー。第 11 回日本臨床腫瘍学会。2013.8.29, 仙台市
 88. 上野誠、森田智、小林智、大川伸一、

- 亀田亮、杉森一哉、金子卓、三輪治生、田中克明、田栗正隆：Randomized phase II study of gemcitabine with an EPA-riched oral supplement in advanced pancreatic cancer 第11回日本臨床腫瘍学会 仙台国際センター、仙台、2013.8.31
89. 五十嵐久人、奥坂拓志、伊藤鉄英、西田俊朗、橋垣 学、木村信之、大木恵美子、澤木 明、山雄健次、今村正之。Phase II study of sunitinib (SU) in Japan patients with well-differentiated pancreatic neuroendocrine tumor (NET). Poster Session 45.PS45: Nevel anti-cancer drugs 2.新規抗がん剤② 第11回日本臨床腫瘍学会学術集会。2013.8.29 日-31 日。於：宮城県仙台市
90. 今岡大、水野伸匡、肱岡範、原和生、田近正洋、田中努、品川秋秀、坂口将文、丹羽康正、山雄健次。膵腺房細胞癌の画像的特徴。第11回日本臨床腫瘍学会学術集会、2013.8.、仙台。
91. 肱岡範、水野伸匡、原和生、今岡大、田近正洋、田中努、丹羽康正、山雄健次。アフィニトールによる間質性肺炎を惹起するも再開継続できている膵内分泌腫瘍の1例。第11回日本臨床腫瘍学会学術集会、2013.8.、仙台。
92. Maeda A, Uesaka K, Fukutomi A, Boku N, Kanemoto H, Konishi M, Matsumoto I, Shimizu Y, Nakamori S, Sakamoto H. JASPAC 01:Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 for resected pancreatic cancer. 第11回日本臨床腫瘍学会学術集会 (JSMO2013) 2013.8.29日-31日 仙台市
93. 伊藤鉄英、五十嵐久人、RT Jensen. 教育講演 8 内分泌癌：膵内分泌腫瘍に対する分子標的薬。第11回日本臨床腫瘍学会学術集会 2013.8.29-31 仙台
94. 五十嵐久人、奥坂拓志、伊藤鉄英、西田俊朗、橋垣 学、木村信之、大木恵美子、澤木 明、山雄健次、今村正之。Phase II Study of Sunitinib(SU) in Japanese Patients with Well-differentiated Pancreatic Neuroendocrine Tumor(NET). 第11回日本臨床腫瘍学会学術集会 2013.8.29-31 仙台
95. 篠原旭、奥山浩之、小林美沙樹、船崎秀樹、高橋秀明、大野泉、清水怜、光永修一、池田公史、和泉啓司郎。進行膵癌における Gemcitabine+Erlotinib 療法による皮膚障害に対するミノサイクリン予防内服の有効性の検討 第11回日本臨床腫瘍学会学術集会 2013.8.29 仙台市
96. 三浦智史、光永修一、清水怜、大野泉、高橋秀明、奥山浩之、桑原明子、池田公史。Characterization of patient with high serum level of IL-6 in advanced pancreatic cancer. 第11回日本臨床腫瘍学会学術集会 2013.8.29 仙台市
97. 奥山浩之、光永修一、桑原明子、高橋秀明、大野泉、清水怜、池田公史。進行膵がんにおける塩酸ゲムシタビン療法の有害事象と炎症性サイトカイン・タンパクの関連 第11回日本臨床腫瘍学会学術集会 2013.8.29 仙台市
98. 田中弘人、光永修一、小林美沙樹、船崎秀樹、高橋秀明、大野泉、清水怜、和泉啓司郎、池田公史。ゲムシタビン耐性進行膵癌に対する S-1 療法の3週レジメンの有効性と安全性—6週レジメンとの比較— 第11回日本臨床腫瘍学会学術集会 2013.08.30 仙台市
99. 浅岡忠史、宮本敦史、山本和義、原口直紹、三宅正和、西川和宏、宮崎道彦、平尾素宏、池田正孝、関本貢嗣、中森正二。膵頭十二指腸切除における術後ドレーン感染の検討 第40回日本膵切研究会 2013.8.30-31, 高松市
100. 木田光広：How to get best your EUS-FNA — Tips & Tricks —, Endoscopy 2013, 2013.8.1-2, バンコック・タイ。
101. 木田光広、三島 孝仁、金子 亨、山内浩史、奥脇 興介、宮澤 志朗、池田 弘子、岩井 知久、菊地 秀彦、荒木 正雄、渡辺 摩也、今泉 弘、小泉 和三郎：【消化器疾患における超音波内視鏡検査-現況と将来展望-】 EUSの現況と新展開 超音波内視鏡検査による消化管疾患の診断の現況, 最新医学, 2013.8, 68(8):1698-1704.
102. 古瀬純司：膵がん化学療法の最新情報—ガイドライン改訂を踏まえて。ラン

- チョンセミナー 6. 第 44 回日本膵臓学会大会. 2013.7.26, 仙台市
103. 岩井 知久, 木田光広, 徳永 周子, 山内 浩史, 奥脇 興介, 宮澤 志朗, 竹澤 三代子, 菊池 秀彦, 渡辺 摩也, 今泉 弘, 小泉 和三郎: 充実性腫瘍に対する逆刃付側孔を有する EUS-FNA 針の診断能, 第 44 回日本膵臓学会大会, 2013.7.25, 仙台, 膵臓(0913-0071)28 巻 3 号 Page403(2013.06).
 104. 山内 浩史, 奥脇 興介, 木田光広, 宮澤 志朗, 岩井 知久, 竹澤 三代子, 今泉 弘, 小泉 和三郎: 膵内分泌腫瘍における EUS 所見と組織学的悪性度との対比, 第 44 回日本膵臓学会大会, 2013.7.25, 仙台, 膵臓, 28 巻 3 号 Page376(2013.06).
 105. 浅岡忠史、宮本敦史、山本和義、池永雅一、宮崎道彦、大宮英泰、平尾素宏、池田正孝、高見康二、藤谷和正、中森正二、関本貢嗣. 切除不能膵癌に対するバイパス手術の治療成績とその予後 第 44 回日本膵臓学会大会 2013 . 7.25-26,仙台市
 106. 福田泰也、浅岡忠史、宮本敦史、山本和義、宮崎道彦、池永雅一、池田正孝、平尾素宏、藤谷和正、関本貢嗣、中森正二. 当科における膵嚢胞性腫瘍の治療成績の検討 第 44 回日本膵臓学会大会 2013 . 7.25-26,仙台市
 107. 宮本敦史、浅岡忠史、山本和義、池永雅一、宮崎道彦、池田正孝、平尾素宏、藤谷和正、関本貢嗣、中森正二. 膵頭十二指腸切除が体重および体組成に及ぼす影響 第 44 回日本膵臓学会大会 2013 . 7.25-26,仙台市
 108. 田口裕紀子、宮本敦史、浅岡忠史、中森正二、中水流正一、三田英治、児玉良典、真能正幸. 無治療で長期生存している浸潤性膵管癌の一例 第 44 回日本膵臓学会大会 2013 . 7.25-26,仙台
 109. 上杉和寛、松本俊彦、浅木彰則、灘野成人、井口東郎. 膵内分泌腫瘍に対するソマトスタチンレセプターを標的とした核医学治療：症例報告. 第 44 回日本膵臓学会大会、2013.7.25-26,仙台.
 110. 松本逸平、上坂克彦、福富晃、朴成和、金本秀行、小西大、金岡祐次、清水泰博、中森正二、坂本裕彦.膵癌切除後補助化学療法における塩酸ゲムシタピン療法と S-1 療法の第 III 相比較試験 (JASPAC 01) 第 68 回日本消化器外科学会総会 2013 . 7.17-19,宮崎市
 111. 古川正幸. 術前の CA19-9 値が膵がん術後の予後予測因子の可能性. 第 44 回日本膵臓学会. 2013.7.25-2013.7.26 : 仙台
 112. 久野晃聖、下川雄三、荒武良総、田尻博敬、西山憲一、古川正幸. 酢酸オクトレオチド投与により腹水の減少、腫瘍の縮小を認めた膵癌、腹膜播種の 1 例 . 第 44 回日本膵臓学会 . 2013.0.25-2013.7.26 : 仙台
 113. 須藤研太郎、横井左奈、大平美紀、中村和貴、原太郎、瀬座勝志、傳田忠道、廣中秀一、三梨桂子、鈴木拓人、相馬寧、北川善康、喜多絵美里、中村奈海、稲垣千晶、山口武人. 切除不能膵癌における EUSFNA 検体を用いた網羅的ゲノム解析による個別化治療確立の試み. 第 44 回日本膵臓学会大会. 2013.. 仙台.
 114. 井口東郎. 膵がんの術後補助化学療法. 愛媛肝胆膵外科セミナー 2013.6 .28 日、松山.
 115. 古瀬純司: 膵癌化学療法—最新情報と今後の展望. 第 22 回日本消化器病学会関東支部例会教育講演. 2013.6.23, つくば市
 116. 古瀬純司: 膵・胆道癌の化学療法—最新情報と今後の展望. 第 99 回日本消化器病学会中国支部例会教育講演 . 2013.6.16, 岡山市
 117. 植田圭二郎、三木正美、藤山 隆、内田匡彦、立花雄一、李 倫學、肱岡真之、新名雄介、五十嵐久人、高柳涼一、伊藤鉄英.BEM+S-1 療法にて癌性腹水が消失した膵癌 StageIVb の 2 症例.第 43 回九州膵研究会.2013.6.20,北九州
 118. 伊藤鉄英.シンポジウム.膵・消化管 NET の現況と新規抗腫瘍薬.第 102 回日本病理学会総会 2013.6.6-8,札幌
 119. 渡辺 晃識, 木田光広, 奥脇 興介, 宮澤 志朗, 岩井 知久, 竹澤 三代子, 渡辺 摩也, 今泉 弘, 小泉 和三郎: IPMN に対する経口膵管鏡 POPS の有用性,

- Progress of Digestive Endoscopy, 2013.6, 82(1):53-55.
120. Makoto Ueno, Shinichi Ohkawa : Nutritional Support for advanced pancreatic cancer. 4th International conference on Cancer Nutrition Therapy The Croatian Academy of Science and Arts, Zagreb, Croatia 2013.5.14-15
 121. M. Ikeda, A Sato, N Mochizuki, K Toyosaki, C Miyoshi, R Fujioka, S Mitsunaga, S Shimizu, I Ohno, H Takahashi, H Okuyama, H Hasegawa, S Nomura, T Ohkubo, S Yomoda, S Kishino, H Esumi. A Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. ASCO Annual Meeting 2013. May31-June04,2013. Chicago, IL, U.S.A. (Abstract 2559)
 122. AkirA. Fukutomi, Katsuhiko Uesaka, Narikazu Boku, Hideyuki Kanemoto, Masaru Konishi, Ipepei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto, Soichiro Morinaga, Osamu Kainuma, Koji Imai, Naohiro Sata, Shoichi Hishinuma, Takayuki Nakamura, Michio Kanai, Satoshi Hirano, Yukinobu Yoshikawa, Yasuo Ohashi, JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer、 ASCO.2013.Chicago
 123. 奥脇 興介, 木田光広, 徳永 周子, 山内 浩史, 宮澤 志朗, 岩井 知久, 竹澤 三代子, 菊地 秀彦, 渡辺 麻也, 今泉 弘, 小泉 和三郎: 膵内分泌腫瘍における EUS 及び EUS-FNA の有用性の検討, 第 85 回日本消化器内視鏡学会総会, 2013.5.12, 京都,
 124. 大塚隆生、田村公二、井手野 昇、安蘇鉄平、河野 博、永吉洋介、伊藤鉄英、五十嵐久人、麻生 暁、牛島泰宏、相嶋慎一、大久保文彦、高畑俊一、上田純二、水元一博、清水周次、田中雅夫.切除可能膵管癌の確定診断に ERCP と EUS-FNA のどちらを先行させるか?.第 85 回 日本消化器内視鏡学会総会 2013.5.10-12,京都
 125. 升谷 寛以, 奥脇 興介, 木田光広, 山内 浩史, 宮澤 志朗, 岩井 知久, 竹澤 三代子, 今泉 弘, 片桐 寛之, 隈元 雄介, 渡邊 昌彦, 蔣 世旭, 三上 哲夫, 三枝 信, 小泉 和三郎: EUS-FNA で診断し得た膵原発 PEComa の 1 切除例, 第 85 回日本消化器内視鏡学会総会, 2013.5.10, 京都, Gastroenterological Endoscopy, 55 巻 Suppl.1 Page1157(2013.04).
 126. 木田光広: 胆膵内視鏡、EUS、EUS-FNA Tips and Tricks, 第 85 回日本消化器内視鏡学会総会, 2013.5.10, 京都, Gastroenterological Endoscopy, 55 巻 Suppl.1 Page886(2013.04).
 127. 古瀬純司: 膵・胆道癌化学療法の最新情報—エビデンスからプラクティスへ。ランチョンセミナー. 第 113 回日本外科学会学術集会. 2013.4.12, 福岡市
 128. 伊藤鉄英、五十嵐久人.ワークショップ. 日本における膵神経内分泌腫瘍(pNET)の現況と内科的治療.第 113 回 日本外科学会定期学術集会.2013.4.11-13,福岡
 129. Furuse J: Combination treatments for pancreatic cancer. Gastrointestinal Cancer Pinnacle I-2. Asian Oncology Summit 2013. 2013.03.24, Bangkok.
 130. 古瀬純司: 外科切除可能膵癌: 3. 補助療法. 膵癌診療ガイドライン拡大改訂委員会. 日本膵臓学会. 2013.03.22, 鹿児島市
 131. 宮澤 志朗, 木田光広, 奥脇 興介, 岩井 和久, 菊地 秀彦, 竹澤 三代子, 荒木 正雄, 渡辺 摩也, 今泉 弘, 小泉 和三郎: 非切除胆膵癌による中下部胆管狭窄に対する Re-Intervention を考慮したメタリックステント選択 Partially covered Wallflex stent と Fully covered Wallflex stent の比較, 第 99 回日本消化器病学会総会, 2013.3.23, 鹿児島. 日本消化器病学会雑誌 110 巻臨増総会 PageA427(2013.02).Gastroenterological Endoscopy 55 巻 Suppl.1 Page1110(2013.04).
 132. 五十嵐久人、河辺 颯、伊藤鉄英.シンポジウム当科における進行性膵神経内分泌腫瘍に対するエベロリムスの使用経験.第 99 回日本消化器病学会総会,2013.3.23 鹿児島
 133. 李 倫學、新名雄介、伊藤鉄英.シンポジウム.膵癌による悪性十二指腸狭窄・閉塞に対する内視鏡的十二指腸ス

- テンティングの問題点.第 99 回 日本
消化器病学会総会 2013.3.23 鹿児島
134. 藤森 尚、河辺 颯、伊藤鉄英、寺松
克人、原田直彦、中牟田 誠.当科にお
ける切除不能胆膵癌に対する化学療法
の現況.第 99 回 日本消化器病学会総
会 2013.3.23 鹿児島
135. 須藤研太郎、山口武人、石原武. 局所
進行膵癌に対する化学放射線療法およ
び化学療法を中心とした治療戦略. 第
99 回日本消化器病学会総会. 2013.. 鹿
児島.
136. 原太郎、山口武人、石原武. 抗腫瘍療
法を前提とした中下部胆道狭窄に対す
る胆管ステントニング-進行膵癌に対
する UMS : Uncovered Metallic Stent の
有用性-. 第 99 回日本消化器病学会、
鹿児島
137. 伊藤鉄英.教育講演会.膵内分泌腫瘍の
現況と治療の進歩.第 18 回 日本消化
器病学会九州支部教育講演会
2013.3.17 福岡
138. 木田光広、三島孝仁、金子亨、渡邊晃
識、徳永周子、山内浩史、奥脇興介、
宮澤志朗、岩井知久、池田弘子、荒木
正雄、竹澤三代子、菊地秀彦、渡辺摩
也、今泉弘、坂口哲章、山田至人、小
泉和三郎: ラジアル式 EUS によるアプ
ローチ, 消化器内視鏡, 2013.2,
25(2):267-273.
139. 井口東郎. 膵がんの化学療法: 現状と
将来展望. 愛媛肝臓外科研究会
2013.2.2 日、松山.
140. 井口東郎. 膵がんの診断と治療: 最近
の知見. 市立宇和島病院市民公開講座
2013.2.2 日、愛媛県宇和島市.
141. Hiroki Yamaue, Masaji Tani, Motoki
Miyazawa, Kenji Yamao, Nobumasa
Mizuno, Takuji Okusaka, Hideki Ueno,
Narikazu Boku, Akira Fukutomi, Hiroshi
Ishii, Shinichi Ohkawa, Masayuki
Furukawa, Hiroyuki Maguchi, Masafumi
Ikeda, Kazuto Nishio, Yasuo Ohashi,
Takuya Tsunoda. Phase II.III clinical trial
with VEGFR2-epitope peptide and
gemcitabine for patients with locally
advanced, metastatic, or unresectable
pancreatic cancer: Pegasus-PC study.
ASCO-GI 2013, San Francisco, CA, USA,
January 2013.
142. Mizuno N, Yamao K, Komatsu Y,
Munakata M, Ishiguro A, Yamaguchi T,
Ohkawa S, Kida M, Ioka T, Takeda K,
Kudo T, Kitano M, Iguchi H, Tsuji A, Ito T,
Tanaka M, Furuse J, Hamada C, Sakata Y.
Randomized phase II trial of S-1 versus
S-1 plus irinotecan (IRIS) in patients with
gemcitabine-refractory pancreatic cancer.
(abstract 263). 2013 Gastrointestinal
Cancers Symposium, 2013.1.25, San
Francisco
143. Katsuhiko Uesaka, Akira Fukutomi,
Narikazu Boku, Hideyuki Kanemoto,
Masaru Konishi, Ipeei Matsumoto, Yuji
Kaneoka, Yasuhiro Shimizu, Shoji
Nakamori, Hirohiko Sakamoto, Soichiro
Morinaga, Osamu Kainuma, Koji Imai,
Naohiro Sata, Shoichi Hishinuma,
Takayuki Nakamura, Michio Kanai,
Satoshi Hirano, Yukinobu Yoshikawa,
Yasuo Ohashi. Randomized phase III trial
of adjuvant chemotherapy with
gemcitabine versus S-1 for resected
pancreatic cancer patients (JASPAC-01
study) 、 Gastrointestinal Cancers
Symposium.2013.San Francisco
144. 伊藤鉄英.生涯教育講演会.膵内分泌腫
瘍の現況と治療の進歩.第 47 回九州支
部主催生涯教育講演会 2013.1.12 福
岡
145. 伊藤鉄英.クリニカルアワー I .臨床の
立場から一機能性膵・消化管神経内分
泌腫瘍の現況と治療.第 22 回臨床内分
泌代謝 Update 2013.1.18 埼玉
146. 木田光広: 【とことん知りたい ERCP
の手技のコツ もう迷わない!後方斜
視鏡の挿入から、乳頭の観察、深部挿
管まで】 コラム 上級者との交代のポ
イント消化器内視鏡レクチャー,
2013.1, 1(3): 524.
147. 木田光広, 荒木 正雄, 三島 孝仁, 渡
邊 晃識, 徳永 周子, 山内 浩史, 奥脇
興介, 宮澤 志朗, 岩井 知久, 竹澤 三
代子, 菊地 秀彦, 渡辺 摩也, 今泉 弘,
小泉 和三郎: 【胆膵内視鏡新潮流】膵
腫瘍の超音波内視鏡診断 膵疾患に対
する EUS-FNA の現況, 肝・胆・膵,
2013.1, 66(1):9-16.

H. 知的財産権の出願・登録状況（予定を含む。）

1. 特許取得
なし。

2. 実用新案登録
なし。

3. その他
特記すべきことなし。

Ⅱ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ueno H, Ioka T, <u>Ikeda M</u> , <u>Ohkawa S</u> , <u>Yanagimoto H</u> , Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, <u>Yamaguchi T</u> , Egawa S, Sato A, Ohhashi Y, <u>Okusaka T</u>	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic pancreatic cancer in Japan and Taiwan: GEST study	J Clin Oncol	31(13)	1640-8	2013
<u>Ikeda M</u> , Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, <u>Ishii H</u> , Furuse J, Sato K, Sato T, <u>Okusaka T</u>	A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer	Int J Radiat Oncol Biol Phys	85(1)	163-9	2013
Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, Shimura K, Nihei T, Nishino T, Nakagawa A, Nakamura K, Hara T, Tada M, Mikata R, Tawada K, <u>Yokosuka O</u> , Nakaji S, <u>Yamaguchi T</u>	Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer	Cancer Chemother Pharmacol	73(2)	389-96	2014

Ioka T, <u>Katayama K,</u> et al	Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan	Jpn J Clin Oncol	43	139-45	2013
<u>古瀬純司</u>	膵・胆道癌薬物療法：臨床試験を読む！—最新の動向と実地診療へのインパクト— 膵・胆道癌化学療法の動向—臨床試験の読み方	胆と膵	34(8)	593-598	2013
原太郎, <u>山口武人,</u> 他	非切除・化学療法施行例に対してステント治療—抗腫瘍療法を前提とした進行膵癌に対する胆管ステントリング—	胆と膵	34	825-832	2013
須藤研太郎, 横井左奈, 大平美紀, 中村和貴, 原太郎, 瀬座勝志, 傳田忠道, 広中秀一, 三梨桂子, 鈴木拓人, 相馬寧, 北川善康, 喜多絵美里, 中村奈海, 稲垣千晶, <u>山口武人</u>	切除不能膵癌におけるEUS-FNA検体を用いた網羅的ゲノム解析による個別化治療確立の試み(解説/特集)	胆と膵	34(2)	185-189	2013
<u>大川伸一</u>	遠隔転移を伴う膵癌に対するFOLFIRINOX療法の第Ⅲ相試験	胆と膵	34(4)	615-618	2013
久野晃聖, 藤山隆, 杉本理恵, 奥村幸彦, <u>古川正幸</u>	GemcitabineおよびS-1に治療抵抗性となった進行膵がんに対する追加化学療法の有効性	膵臓	28	56-61	2013

Ⅲ. 研究成果の刊行物・別刷り

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, and Masao Tanaka

See accompanying editorial on page 1621

Author affiliations appear at the end of this article.

Published online ahead of print at www.jco.org on April 1, 2013.

Written on behalf of the Gemcitabine and S-1 Trial Group.

Supported by Taiho Pharmaceutical and TTY Biopharm.

Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information: NCT00498225.

Corresponding author: Takuji Okusaka, MD, Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; e-mail: tokusaka@ncc.go.jp.

© 2013 by American Society of Clinical Oncology

0732-183X/13/3113w-1640w/\$20.00

DOI: 10.1200/JCO.2012.43.3680

A B S T R A C T

Purpose

The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival.

Patients and Methods

The participants were chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m² on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle).

Results

In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; $P < .001$ for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; $P = .15$). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group.

Conclusion

Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.

J Clin Oncol 31:1640-1648. © 2013 by American Society of Clinical Oncology

INTRODUCTION

Pancreatic cancer (PC) is currently the eighth leading cause of cancer-related mortality worldwide, with an estimated 266,000 deaths in 2008.¹ Gemcitabine became the standard treatment for advanced PC, improving overall survival (OS) compared with fluorouracil.² Although various gemcitabine-based combination regimens have been evaluated, only erlotinib added to gemcitabine showed a survival benefit over gemcitabine, and that was marginal.³

Fluorouracil/leucovorin plus irinotecan plus oxaliplatin (FOLFIRINOX), a gemcitabine-free combination regimen, has recently demonstrated a clear survival benefit compared with gemcitabine for patients with metastatic PC who have a performance status of 0 to 1.⁴ However, because FOLFIRINOX is associated with significant toxicity, this regimen must be limited to patients with good performance status and requires close monitoring.⁵

In Japan, clinical trials of S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) have been conducted since the early 2000s for patients with PC. S-1

is an oral fluoropyrimidine derivative shown to be effective for gastric and various other types of cancers.^{6,7} Phase II studies of S-1 as first-line therapy for metastatic PC resulted in good response rates of 21.1% to 37.5%.^{8,9} Consequently, S-1 was approved for the indication of PC in Japan in 2006. Development of gemcitabine plus S-1 (GS) studies have also been initiated, mainly in Japan, and two phase II studies reported high response rates of 44.4% to 48.5% and good median OS of 10.1 to 12.5 months.^{10,11}

Because S-1 and GS have shown promising activity in PC, the present randomized phase III study (GEST [Gemcitabine and S-1 Trial] study) was designed to evaluate whether S-1 alone is noninferior to gemcitabine and whether GS is superior to gemcitabine alone for locally advanced and metastatic PC with respect to OS.

PATIENTS AND METHODS

Study Design

This randomized phase III study, sponsored by Taiho Pharmaceutical in Japan and TTY Biopharm in Taiwan, was conducted as a postmarketing study in Japan and as a registration study in Taiwan and was in compliance with the Declaration of Helsinki. Data were collected by a contract research organization contracted by the sponsors and were analyzed by a bio-statistician (Y.O.). An independent data and safety monitoring committee reviewed efficacy and safety data. The study was approved by the ethics committee or institutional review board of each participating center.

Patients

All patients provided written informed consent. Enrollment criteria were locally advanced or metastatic PC, histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma, no prior chemotherapy or radiotherapy for PC, age of more than 20 years (the protocol was amended to restrict the eligible age to < 80 years after four of the first eight patients who were ≥ 80 years experienced serious adverse events), an Eastern Cooperative Oncology Group performance status score of 0 to 1, and adequate organ functions (see Appendix, online only).

Treatment

Random assignment was performed centrally with stratification by extent of disease (locally advanced disease v metastatic disease) and institution

using the minimization method. Patients allocated to gemcitabine alone received gemcitabine at a dose of 1,000 mg/m² intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Patients allocated to S-1 alone received S-1 orally twice daily at a dose according to the body-surface area (BSA) (< 1.25 m², 80 mg/d; ≥ 1.25 to < 1.5 m², 100 mg/d; ≥ 1.5 m², 120 mg/d) on days 1 through 28 of a 42-day cycle. Patients allocated to GS received gemcitabine at a dose of 1,000 mg/m² on days 1 and 8 plus S-1 orally twice daily at a dose according to the BSA (< 1.25 m², 60 mg/d; ≥ 1.25 to < 1.5 m², 80 mg/d; ≥ 1.5 m², 100 mg/d) on days 1 through 14 of a 21-day cycle. The dose levels of S-1 used in the GS group were based on the results of a previous phase II study of GS, in which 1,000 mg/m² of gemcitabine was combined with 120 mg/d, 100 mg/d, and 80 mg/d of S-1. In that study, the rate of treatment withdrawal due to adverse events was 41% (22 of 54 patients), the rate of grade 3 or worse neutropenia was 80%, and the dose was reduced in 56% of the patients (30 of 54 patients).¹¹ Consequently, 20 mg/d lower doses of S-1 than those used in the S-1 monotherapy group were used in the GS group in the present study.

In the event of predefined toxic events, protocol-specified treatment modifications were permitted (see Appendix).

Assessments

Physical examinations, CBCs, and biochemistry tests were usually checked at 2-week intervals in the S-1 group and at each time of administration of gemcitabine both in the gemcitabine group and in the GS group. All adverse events were assessed according to the Common Terminology Criteria for Adverse Events, version 3.0. Computed tomography or magnetic resonance imaging was performed every 6 weeks until disease progression, and response was assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0.¹² Quality of life was assessed using the EuroQol 5 Dimension questionnaire¹³ at baseline and 6, 12, 24, 48, and 72 weeks after the study treatment had begun.

Statistical Analysis

The primary end point was OS, defined as time from date of random assignment to date of death from any cause. Secondary end points were progression-free survival (PFS), objective response rate, safety, and quality of life. PFS was counted from the date of random assignment to the date of death without progression or of progression as confirmed by the investigator's assessment. The median OS was assumed to be 7.5 months in the gemcitabine group, 8.0 months in the S-1 group, and 10.5 months in the GS group. To maintain a one-sided significance level of .025 for the entire study while testing two hypotheses (ie, noninferiority and superiority), the one-sided significance




Fig 1. CONSORT diagram. GS, gemcitabine plus S-1.

level for each comparison was set at .0125. The statistical considerations are detailed in the Appendix.

The superiority of GS was evaluated by the stratified log-rank test. To assess the noninferiority of S-1, we used the Cox proportional hazards model to calculate two-sided, 97.5% CIs of the hazard ratio (HR). The noninferiority margin of S-1 was set at 1.33; that is, the null hypothesis was that the median OS with S-1 would be approximately 2 months shorter than with gemcitabine. We decided this setting was justified considering the convenience of S-1 and because there are few effective drugs for the disease. Furthermore, to interpret the obtained data, the Bayesian analysis of the log HR on the basis of the noninformative prior distribution was preplanned. Posterior probability with log HR within a stricter threshold (log 1.15) was also calculated.¹⁴

In each assigned group, the time-to-event distribution was estimated with the Kaplan-Meier method. The 95% CI of the median survival time was calculated by the method of Brookmeyer and Crowley.¹⁵ In addition, the Greenwood formula¹⁶ was used to calculate the 95% CI for survival rates. In subgroup analyses, interaction tests were performed to assess the homogeneity of the effect of treatment on OS.

The primary end point was analyzed for the full analysis set. All *P* value evaluations were two-tailed. Data analyses were done with SAS, version 9.1.3 (SAS Institute, Cary, NC).

RESULTS

Patients

Between July 2007 and October 2009, a total of 834 patients were enrolled from 75 institutions in Japan and Taiwan (768 in Japan and 66 in Taiwan). Two patients in the GS group were excluded from the study because enrollment was conducted before obtaining written informed consent. The remaining 832 patients were included in the full analysis set and used to calculate OS and PFS (Fig 1). The three treatment groups were well balanced with respect to demographic and baseline characteristics (Table 1).

Study Treatment

The median duration of treatment was 2.6 months in the gemcitabine group, 2.6 months in the S-1 group, and 4.3 months in the GS group. The main reasons for treatment discontinuation were either disease progression (202 patients [72.9%] in the gemcitabine group,

Table 1. Demographics and Baseline Characteristics of Patients (full-analysis set population)

Characteristic	Gemcitabine (n = 277)		S-1 (n = 280)		GS (n = 275)		Total (N = 832)	
	No.	%	No.	%	No.	%	No.	%
Sex								
Male	170	61.4	170	60.7	158	57.5	498	59.9
Female	107	38.6	110	39.3	117	42.5	334	40.1
Age, years								
< 65	134	48.4	145	51.8	137	49.8	416	50.0
≥ 65	143	51.6	135	48.2	138	50.2	416	50.0
ECOG PS								
0	181	65.3	178	63.6	172	62.5	531	63.8
1	96	34.7	102	36.4	103	37.5	301	36.2
Extent of disease								
Locally advanced	66	23.8	68	24.3	68	24.7	202	24.3
Metastatic	211	76.2	212	75.7	207	75.3	630	75.7
Type of tumor								
Adenocarcinoma	272	98.2	276	98.6	272	98.9	820	98.6
Adenosquamous carcinoma	5	1.8	4	1.4	3	1.1	12	1.4
Pancreas excision								
No	254	91.7	264	94.3	248	90.2	766	92.1
Yes	23	8.3	16	5.7	27	9.8	66	7.9
Tumor location*								
Head	122	44.0	110	39.3	116	42.2	348	41.8
Body	88	31.8	124	44.3	102	37.1	314	37.7
Tail	68	24.5	55	19.6	66	24.0	189	22.7
Biliary drainage								
No	202	72.9	217	77.5	209	76.0	628	75.5
Yes	75	27.1	63	22.5	66	24.0	204	24.5
CEA, ng/mL								
Median	5.7		5.6		5.9		5.7	
IQR	3.0-20.1		2.5-18.4		2.5-20.7		2.6-19.5	
CA19-9, U/mL								
Median	1,044		726		441		712	
IQR	52-5,002		64-5,000		45-5,090		55-5,002	
CRP, mg/dL								
Median	0.40		0.50		0.40		0.43	
IQR	0.11-1.38		0.18-1.57		0.15-1.60		0.15-1.57	

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; GS, gemcitabine plus S-1; IQR, interquartile range.

*Including patients with tumors involving multiple sites.

215 [76.8%] in the S-1 group, and 162 [58.9%] in the GS group) or adverse events (40 patients [14.4%] in the gemcitabine group, 38 [13.6%] in the S-1 group, and 76 [27.6%] in the GS group). The median relative dose-intensity was 83.0% in the gemcitabine group, 96.1% in the S-1 group, and 83.3% for gemcitabine and 87.4% for S-1 in the GS group.

Survival

The median duration of follow-up for surviving patients was 18.4 months (range, 0.3 to 36.9 months) as of July 31, 2010. The analysis of OS was based on 710 deaths (85.3%) among the 832 patients. The median OS was 8.8 months (95% CI, 8.0 to 9.7) in the gemcitabine group, 9.7 months (95% CI, 7.6 to 10.8) in the S-1 group, and 10.1 months (95% CI, 9.0 to 11.2) in the GS group (Fig 2A). OS rates at 12 and 24 months were respectively 35.4% and 9.2% in the gemcitabine group, 38.7% and 12.7% in the S-1 group, and 40.7% and 14.5% in the GS group. The noninferiority of S-1 to gemcitabine with respect to OS was demonstrated (HR, 0.96; 97.5% CI, 0.78 to 1.18; $P < .001$ for

noninferiority). The Bayesian posterior probability that the HR of S-1 relative to gemcitabine would be less than 1.15 was calculated to be 98% on the basis of the noninformative prior distribution. However, GS failed to improve OS at a statistically significant level as compared with gemcitabine (HR, 0.88; 97.5% CI, 0.71 to 1.08; $P = .15$).

The analysis of PFS was based on 793 events (95.3%) among the 832 patients. The median PFS was 4.1 months (95% CI, 3.0 to 4.4) in the gemcitabine group, 3.8 months (95% CI, 2.9 to 4.2) in the S-1 group, and 5.7 months (95% CI, 5.4 to 6.7) in the GS group (Fig 2B). PFS rates at 6 and 12 months were respectively 29.8% and 9.1% in the gemcitabine group, 26.9% and 7.2% in the S-1 group, and 47.9% and 20.3% in the GS group. S-1 was shown to be noninferior to gemcitabine with respect to PFS (HR, 1.09; 97.5% CI, 0.90 to 1.33; $P = .02$ for noninferiority), and GS significantly improved PFS compared with gemcitabine (HR, 0.66; 97.5% CI, 0.54 to 0.81; $P < .001$).

Subgroup analyses of survival according to pretreatment characteristics showed no significant interaction between S-1 and gemcitabine in any subgroup (Fig 3A). However, GS showed a favorable HR compared with gemcitabine in the subsets of patients with locally advanced disease or patients with a performance status of 1 (Fig 3B).




Fig 2. Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival according to treatment group. GS, gemcitabine plus S-1.

Response to Therapy

The objective response rate was 13.3% (95% CI, 9.3 to 18.2) in the gemcitabine group, 21.0% (95% CI, 16.1 to 26.6) in the S-1 group, and 29.3% (95% CI, 23.7 to 35.5) in the GS group (Table 2). The objective response rate was significantly higher in the S-1 group ($P = .02$) and in the GS group ($P < .001$) than in the gemcitabine group.

Second-Line Chemotherapy

Second-line chemotherapy was performed in 184 patients (66.4%) in the gemcitabine group, 185 (66.1%) in the S-1 group, and 172 (62.5%) in the GS group. In the gemcitabine group, 140 patients (50.5%) received S-1 alone or S-1-based regimens, and in the S-1 group 162 (57.9%) received gemcitabine alone or gemcitabine-based regimens as second-line chemotherapy. The most common second-line regimens in the GS group were gemcitabine alone (61 patients), GS (53 patients), S-1 alone (24 patients), irinotecan (six patients), and fluorouracil/leucovorin plus oxaliplatin (four patients). In Japan and Taiwan, the use of treatments such as erlotinib, oxaliplatin, and irinotecan for PC was not approved at the time of this study; hence gemcitabine, S-1, or both were used in most patients as second-line chemotherapy.

Adverse Events and Quality-Adjusted Life-Years

The major grade 3 or worse adverse events are listed in Table 3. Patients in the gemcitabine group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, elevated AST levels, and elevated ALT levels as compared with patients in the S-1 group. However, the incidence of grade 3 or worse diarrhea was higher in the S-1 group than in the gemcitabine group. Patients in the GS group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, rash, diarrhea, vomiting, and stomatitis than patients in the gemcitabine group.

There were three deaths considered possibly related to the protocol treatment (interstitial lung disease, sepsis, and acute hepatitis B) in the gemcitabine group, one in the S-1 group (unknown cause), and




Fig 3. Forest plots of treatment effects on overall survival in subgroup analyses. Forest plots show effects on overall survival of patients in each subgroup. (A) S-1; (B) gemcitabine plus S-1 (GS). Each blue circle shows the treatment response. ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

four in the GS group (unknown cause associated with myelosuppression, cerebral infarction, cerebrovascular disorder, and interstitial lung disease). The results of quality-adjusted life-years (QALYs) are in the Appendix and the details of quality-of-life assessments will be reported elsewhere.

DISCUSSION

The overall and PFS curves in the S-1 group were nearly identical to those in the gemcitabine group, confirming the noninferiority of S-1

to gemcitabine in terms of OS and PFS (Fig 2A, 2B). Toxicity profiles of these two drugs differed slightly: gemcitabine tended to show hematologic toxicity, whereas S-1 tended to show GI toxicity. However, both S-1 and gemcitabine were generally well tolerated. Furthermore, the results of QALY evaluation demonstrated that S-1 and gemcitabine were equivalent. Hence our results suggest that S-1 can be used as first-line therapy as a convenient oral alternative for locally advanced and metastatic PC. To the best of our knowledge, this is the first phase III study to demonstrate the noninferiority of a single anticancer agent to gemcitabine alone for locally advanced and metastatic PC.

GS or S-1 v Gemcitabine for Pancreatic Cancer

Table 2. Objective Response Rates (patients with measurable lesions)

Variable	Gemcitabine (n = 241)		S-1 (n = 248)		GS (n = 242)		<i>P</i> (χ^2 test)	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
Response								
Complete response	1	0.4	0	0	2	0.8		
Partial response	31	12.9	52	21.0	69	28.5		
Stable disease	119	49.4	105	42.3	102	42.1		
Progressive disease	75	31.1	69	27.8	37	15.3		
Objective response rate*	32	13.3	52	21.0	71	29.3	.02	< .001
95% CI	9.3 to 18.2		16.1 to 26.6		23.7 to 35.5			
Disease control rate†	151	62.7	157	63.3	173	71.5	.88	.04
95% CI	56.2 to 68.8		57.0 to 69.3		65.4 to 77.1			

Abbreviation: GS, gemcitabine plus S-1.

*The objective response rate was defined as the proportion of patients who had a complete response or partial response.

†The disease control rate was defined as the proportion of patients who had a complete response, partial response, or stable disease.

At the time of planning this study, the participants of nearly all phase III trials included both patients with locally advanced as well as those with metastatic PC. However, because locally advanced and metastatic diseases are two clinical entities, it is recently recommended that patients with locally advanced disease should be studied separately from those with metastatic disease.¹⁷ Although this study included locally advanced disease, subgroup analysis of extent of disease showed no significant interaction between S-1 and gemcitabine (Fig 3A). Moreover, the OS curve in the S-1 group was still similar to those in the gemcitabine group in both locally advanced and metastatic disease (Fig 4A, 4B). Regarding pathologic diagnosis, our study included adenosquamous carcinoma, although its percentage was very low (1.4% of whole population). When the data were reanalyzed after

excluding patients with adenosquamous carcinoma, the results for OS for gemcitabine versus S-1 was unchanged (HR, 0.96; 95% CI, 0.81 to 1.15). The selection of one treatment over the other will depend primarily on patient preference, clinical factors, or drug costs, as biomarkers indicating effective use of S-1 or gemcitabine do not exist at this time.

Regarding GS, the OS did not differ significantly from gemcitabine, although the PFS was significantly longer in the GS group. Second-line chemotherapy mainly with S-1 in the gemcitabine group may be one reason for this discrepancy. The median OS in the gemcitabine group was 8.8 months, which is longer than those previously reported for gemcitabine in other phase III studies for locally advanced and metastatic PC.^{2,3,18-24} Although the efficacy of second-line

Table 3. Grade 3 or Worse Adverse Events (safety population)

Event	Gemcitabine (n = 273)		S-1 (n = 272)		GS (n = 267)		<i>P</i> (Fisher's exact test)	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
Hematologic								
Leukocytes	51	18.7	10	3.7	101	37.8	< .001	< .001
Neutrophils	112	41.0	24	8.8	166	62.2	< .001	< .001
Platelets	30	11.0	4	1.5	46	17.2	< .001	.05
Hemoglobin	39	14.3	26	9.6	46	17.2	.11	.41
Nonhematologic								
ALT	41	15.0	16	5.9	29	10.9	< .001	.16
AST	41	15.0	21	7.7	32	12.0	.01	.32
Bilirubin	26	9.5	39	14.3	23	8.6	.09	.77
Fatigue	10	3.7	18	6.6	13	4.9	.13	.53
Rash	2	0.7	2	0.7	11	4.1	1.00	.01
Anorexia	20	7.3	31	11.4	25	9.4	.11	.44
Diarrhea	3	1.1	15	5.5	12	4.5	.004	.02
Mucositis/stomatitis	0	0.0	2	0.7	6	2.2	.25	.01
Nausea	5	1.8	5	1.8	12	4.5	1.00	.09
Vomiting	2	0.7	4	1.5	12	4.5	.45	.006
Febrile neutropenia	1	0.4	1	0.4	5	1.9	1.00	.12
Infection with normal ANC	6	2.2	7	2.6	6	2.2	.79	1.00
Pneumonitis	5	1.8	0	0.0	2	0.7	.06	.45

NOTE. Grades of adverse events were defined according to the Common Terminology Criteria for Adverse Events (version 3.0). Abbreviations: ANC, absolute neutrophil count; GS, gemcitabine plus S-1.




Fig 4. Kaplan-Meier estimates of overall survival in (A) locally advanced disease and (B) metastatic disease. GS, gemcitabine plus S-1.

therapy was not analyzed in this study, a phase II study of second-line S-1 in patients with gemcitabine-refractory PC showed a 15% response rate and 58% disease control rate.²⁵ Compared with the GS group, which had no promising second-line therapy, the use of S-1 as second-line therapy in the gemcitabine group might have contributed to prolonged survival.

The lack of a significant difference in OS between gemcitabine and GS suggests that gemcitabine and S-1 could be used sequentially rather than concurrently. However, the GS group showed a high response rate and favorable PFS, with a better HR of 0.66 compared with other gemcitabine-based combination regimens in other phase III studies (HR = 0.75 to 1.07).^{3,18,20,22,24} Furthermore, the GS group showed a favorable HR for OS in patients with locally advanced disease or patients with a performance status of 1 in the subgroup analyses. Therefore, it is speculated that there may be room to select GS therapy, depending on the profile of the patients and further investigations.

Regarding oral fluoropyrimidines other than S-1, capecitabine has been studied in patients with PC, mainly in the West. In two phase

III studies, a combination of gemcitabine plus capecitabine did not significantly prolong survival as compared with gemcitabine alone.^{19,20} The results of a meta-analysis of these phase III studies, however, demonstrated that survival was significantly prolonged by combined treatment, with an HR of 0.86,²⁰ which is similar to the HR for GS in the present study (0.88).

One limitation of our study is that it is uncertain whether our results can be simply extrapolated to Western patients because pharmacokinetics and pharmacodynamics of S-1 between Westerners and East Asians may be different.^{26,27} Although S-1 is available for PC only in Japan at the moment, if S-1 is used in Western patients, its effectiveness should be monitored and the dose should be carefully adjusted accordingly. Another potential limitation is that the protocol-specified noninferiority margin of 1.33 may be large. However, the result of point estimate of the HR of S-1 was 0.96 and actual upper limit of the 97.5% CI was 1.18, which was sufficiently lower than the prespecified margin of 1.33. Furthermore, Bayesian posterior probability with log HR within a stricter threshold (log 1.15) was 98%.

Given that most gemcitabine-based combination regimens have not been shown to be significantly superior to gemcitabine alone and that FOLFIRINOX has demonstrated overwhelming superiority to gemcitabine in a phase III study, reporting an HR of 0.57,⁴ the development of gemcitabine-free combination regimens for first-line treatment seems to be warranted. However, because FOLFIRINOX requires the placement of a central venous access port for continuous intravenous infusion of fluorouracil, it can be expected that S-1, an oral fluoropyrimidine, will replace the continuous infusion of fluorouracil in the future.

In conclusion, this study has verified the noninferiority of S-1 to gemcitabine, thereby suggesting that S-1 can be used as first-line therapy for locally advanced and metastatic PC. Because S-1 was confirmed to be a key treatment for PC, S-1-based regimens are expected to be developed in the future to improve the management of this formidable disease.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory Role:** Hideki Ueno, Taiho Pharmaceutical (C); Tatsuya Ioka, Taiho Pharmaceutical (U); Shinichi Ohkawa, Taiho Pharmaceutical (C); Narikazu Boku, Taiho Pharmaceutical (U); Kenji Yamao, Taiho Pharmaceutical (C); Ann-Lii Cheng, Boehringer Ingelheim (C), sanofi-aventis (C), TTY Biopharm (C); Kazuhiro Mizumoto, Taiho Pharmaceutical (C); Jen-Shi Chen, TTY Biopharm (C); Junji Furuse, Bayer (C), GlaxoSmithKline (C), Kowa (C), Novartis (C), Taiho Pharmaceutical (C); Akihiro Funakoshi, Taiho Pharmaceutical (C); Takashi Hatori, Taiho Pharmaceutical (C); Taketo Yamaguchi, Taiho Pharmaceutical (C); Atsushi Sato, Taiho Pharmaceutical (C); Yasuo Ohashi, Taiho Pharmaceutical (C); Takuji Okusaka, Taiho Pharmaceutical (C); Masao Tanaka, Taiho Pharmaceutical (C) **Stock**

Ownership: None **Honoraria:** Hideki Ueno, Taiho Pharmaceutical, Eli Lilly; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly, Chugai; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical, Eli Lilly; Masayuki Sho, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Eli Lilly; Akihiro Funakoshi, Taiho Pharmaceutical; Atsushi Sato, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical; Takuji Okusaka, Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical **Research Funding:** Hideki Ueno, Taiho Pharmaceutical; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly, Chugai, Oncotherapy Science, Yakult, Abbott, Amgen; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical Co. Ltd; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical; Tomotaka Shimamura, Taiho Pharmaceutical; Masayuki Sho, Taiho Pharmaceutical; Masayuki Kitano, Taiho Pharmaceutical; Ann-Lii Cheng, TTY Biopharm; Kazuhiro Mizumoto, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Pfizer, Yakult; Akihiro Funakoshi, Taiho Pharmaceutical; Takashi Hatori, Taiho Pharmaceutical; Taketo Yamaguchi, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical; Takuji Okusaka,

Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical, Eli Lilly **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka

Provision of study materials or patients: Masayuki Kitano, Masao Tanaka

Collection and assembly of data: Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Takuji Okusaka, Masao Tanaka

Data analysis and interpretation: Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Jemal A, Bray F, Center MM, et al: Global cancer statistics. *CA Cancer J Clin* 61:69-90, 2011
- Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. *J Clin Oncol* 15:2403-2413, 1997
- Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 25:1960-1966, 2007
- Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364:1817-1825, 2011
- Saif MW, Chabot J: Chemotherapy: Metastatic pancreatic cancer—Is FOLFIRINOX the new standard? *Nat Rev Clin Oncol* 8:452-453, 2011
- Saif MW, Syrigos KN, Katirtzoglou NA: S-1: A promising new oral fluoropyrimidine derivative. *Expert Opin Investig Drugs* 18:335-348, 2009
- Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): Its clinical usefulness and future vistas. *Jpn J Clin Oncol* 39:2-15, 2009
- Ueno H, Okusaka T, Ikeda M, et al: An early phase II study of S-1 in patients with metastatic pancreatic cancer. *Oncology* 68:171-178, 2005
- Okusaka T, Funakoshi A, Furuse J, et al: A late phase II study of S-1 for metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 61:615-621, 2008
- Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. *Br J Cancer* 94:1575-1579, 2006
- Ueno H, Okusaka T, Furuse J, et al: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. *Jpn J Clin Oncol* 41:953-958, 2011
- Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
- EuroQol: A new facility for the measurement of health-related quality of life—The EuroQol Group. *Health Policy* 16:199-208, 1990
- Spiegelhalter DJ, Freedman LS, Parmar MKB: Bayesian approaches to randomized trials. *J R Stat Soc* 157:357-387, 1994
- Brookmeyer R, Crowley J: A confidence interval for the median survival time. *Biometrics* 38:29-41, 1982
- Kalbfleisch JD, Prentice RL: *The Statistical Analysis of Failure Time Data*. New York, NY, Wiley, 1980, p. 14
- Philip PA, Mooney M, Jaffe D, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 27:5660-5669, 2009
- Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 24:3946-3952, 2006
- Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. *J Clin Oncol* 25:2212-2217, 2007
- Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 27:5513-5518, 2009
- Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 27:3778-3785, 2009
- Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. *J Clin Oncol* 28:3605-3610, 2010
- Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 28:3617-3622, 2010
- Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. *Lancet Oncol* 12:256-262, 2011
- Morizane C, Okusaka T, Furuse J, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 63:313-319, 2009
- Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. *J Clin Oncol* 26:2118-2123, 2008
- Chuah B, Goh BC, Lee SC, et al: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. *Cancer Sci* 102:478-483, 2011

Affiliations

Hideki Ueno and Takuji Okusaka, National Cancer Center Hospital; Junji Furuse, Kyorin University; Takashi Hatori, Tokyo Women's Medical University; Atsushi Sato, Showa University Hospital; Yasuo Ohashi, The University of Tokyo, Tokyo; Tatsuya Ioka, Osaka Medical

Center for Cancer and Cardiovascular Diseases, Osaka; Masafumi Ikeda, National Cancer Center Hospital East, Kashiwa; Shinichi Ohkawa, Kanagawa Cancer Center, Yokohama; Hiroaki Yanagimoto, Kansai Medical University, Hirakata; Narikazu Boku and Akira Fukutomi, Shizuoka Cancer Center, Sunto-gun; Kazuya Sugimori, Yokohama City University Medical Center, Yokohama; Hideo Baba, Kumamoto University, Kumamoto; Kenji Yamao, Aichi Cancer Center Hospital, Nagoya; Tomotaka Shimamura, Saitama Cancer Center, Saitama; Masayuki Sho, Nara Medical University, Kashihara; Masayuki Kitano, Kinki University, Osakasayama; Kazuhiro Mizumoto and Masao Tanaka, Kyushu University; Akihiro Funakoshi, Fukuoka Sanno Hospital, Fukuoka; Taketo Yamaguchi, Chiba Cancer Center, Chiba; Shinichi Egawa, Tohoku University, Sendai, Japan; Ann-Lii Cheng, National Taiwan University Hospital, Taipei; and Jen-Shi Chen, Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.

Simplify Your Search With *JCO* Subject Collections

Subject Collections are topic-specific archives of articles published on jco.org that make it easy for you to find the research you need. Instead of random, time-consuming keyword searches, *JCO* Subject Collections allow you to quickly browse your interest areas for articles on specific diseases and treatments. Best of all, by signing up for Collection Alerts, you'll receive e-mail notification whenever *JCO* publishes an article in your interest area.

Sign up today at jco.org/collections.



Acknowledgment

We thank all the patients, their families, the investigators and medical staff and Yuji Sato and his clinical study team, Taiho Pharmaceutical, and TTY Biopharm for their participation in the study. We also thank J. Patrick Barron of the International Medical Communications Center of Tokyo Medical University, a remunerated consultant of Taiho Pharmaceutical, for his review of this article.

Appendix

Members of the Gemcitabine and S-1 Trial Group

Steering committee. T. Okusaka, S. Egawa, J. Furuse, T. Yamaguchi, H. Ueno, T. Hatori, S. Ohkawa, N. Boku, K. Yamao, T. Ioka, A. Funakoshi, K. Mizumoto, M. Tanaka.

Independent data and safety monitoring committee. A. Nakao, I. Hyodo, S. Morita; Medical Advisor: A. Sato; Statistical Analyst: Y. Ohashi.

Principal investigators. National Cancer Center Hospital: T. Okusaka; Osaka Medical Center for Cancer and Cardiovascular Diseases: T. Ioka; National Cancer Center Hospital East: M. Ikeda, K. Nakachi; Kanagawa Cancer Center: S. Ohkawa; Kansai Medical University: H. Yanagimoto; Yokohama City University Medical Center: K. Sugimori; Shizuoka Cancer Center: A. Fukutomi; Kumamoto University: H. Baba; Saitama Cancer Center: T. Shimamura, H. Hara; Aichi Cancer Center Hospital: K. Yamao; Nara Medical University: M. Sho; Kinki University, Department of Gastroenterology and Hepatology: M. Kitano; Sapporo-Kosei General Hospital: H. Miyagawa; Kyushu University, First Department of Surgery: K. Mizumoto; Jichi Medical University Hospital: H. Fujii; National Hospital Organization Osaka National Hospital: S. Nakamori; Kinki University, Department of Medical Oncology: T. Satoh, S. Ueda; Tochigi Cancer Center: Y. Hamamoto, E. Warita; Kyushu University, Department of Hepatology and Pancreatology: T. Ito; Teine-Keijinkai Hospital: H. Maguchi; Kyorin University: J. Furuse; Kyoto University Hospital: S. Matsumoto; Saitama Medical University International Medical Center: Y. Sasaki; Hokkaido University Hospital: Y. Komatsu; Tokyo Women's Medical University: M. Yamamoto; Saku Central Hospital: T. Hisa; Osaka City Juso Hospital: T. Yamazaki, O. Kurai; Kochi Health Sciences Center: A. Tsuji; National Kyushu Cancer Center: A. Funakoshi, M. Furukawa; Niigata Cancer Center Hospital: Y. Tsuchiya; Chiba Cancer Center: T. Yamaguchi; Osaka Red Cross Hospital: Y. Okabe; Tohoku University, Division of Gastroenterology: K. Sato; Tohoku University, Division of Gastroenterological Surgery: F. Motoi; Matsusaka Chuo General Hospital: H. Naota; Kyoto Second Red Cross Hospital: K. Yasuda; Hyogo College of Medicine: J. Fujimoto; Toyama University Hospital: A. Hosokawa; Fukuoka University Chikushi Hospital: T. Ueki; Hokkaido Social Insurance Hospital: K. Furuya; Kameda Medical Center: Y. Oyama; Nagoya Medical Center: H. Iwase; Shinshu University Hospital: N. Arakura; Yodogawa Christian Hospital: A. Watanabe; Osaka Medical College Hospital: H. Takiuchi; Kitano Hospital: S. Yazumi; Sakai Municipal Hospital: H. Ohzato; Kawasaki Medical School Hospital: K. Yoshida; Onomichi General Hospital: K. Hanada; Kagawa University Hospital: F. Goda; Shikoku Cancer Center: H. Iguchi; Keio University Hospital: T. Hibi; Osaka City General Hospital: H. Nebiki; Chiba University Hospital: T. Ishihara; Nippon Medical School Hospital: E. Uchida; Tokai University Hospital: T. Imaizumi; Nagoya City University Hospital: H. Ohara; Aichi Cancer Center Aichi Hospital: H. Kojima; Osaka City University Hospital: N. Yamada; Wakayama Medical University Hospital: H. Yamaue; Tokyo Medical University Hospital: F. Moriyasu; Showa University Northern Yokohama Hospital: K. Shimada; Shizuoka General Hospital: K. Matsumura; Hyogo Cancer Center: H. Nishisaki; Kanazawa University Hospital: S. Yano; Hiroshima Prefectural Hospital: K. Shinozaki; University of Miyazaki Hospital: H. Inatsu; Linkou Chang Gung Memorial Hospital and Chang Gung University: Jen-Shi Chen; National Taiwan University Hospital: Chiun Hsu; Taipei Veterans General Hospital: Jin-Hwang Liu; Chang Gung Medical Foundation, Kaohsiung: Kun-Ming Rau; Chung-Ho Memorial Hospital, Kaohsiung Medical University: Sheng-Fung Lin; China Medical University Hospital: Chang-Fang Chiu; Mackay Memorial Hospital, Taipei: Ruey-Kuen Hsieh; Changhua Christian Hospital: Cheng-Shyong Chang; Chi Mei Medical Center, Yong Kang: Wei-Shou Huang; Chi Mei Medical Center, Liou Ying: Wen-Tsun Huang; National Cheng Kung University Hospital: Wu-Chou Su.

Details of Adequate Organ Functions in Enrollment Criteria and Main Exclusion Criteria

Adequate organ functions were defined as follows: leukocyte count $\geq 3,500/\mu\text{L}$, neutrophil count $\geq 2,000/\mu\text{L}$, platelet count $\geq 100,000/\mu\text{L}$, hemoglobin level $\geq 9.0\text{ g/dL}$, serum creatinine level $\leq 1.2\text{ mg/dL}$, creatinine clearance $\geq 50\text{ mL/min}$, serum AST and ALT levels $\leq 150\text{ U/L}$, and serum total bilirubin level $\leq 2.0\text{ mg/dL}$ or $\leq 3.0\text{ mg/dL}$ if biliary drainage was performed.

Main exclusion criteria were as follows: pulmonary fibrosis or interstitial pneumonia; watery diarrhea; active infection; marked pleural effusion or ascites; and serious complications such as heart failure, peptic ulcer bleeding, or poorly controlled diabetes. Pancreatic cancers other than adenocarcinoma or adenosquamous carcinoma (eg, anaplastic carcinoma) were excluded from the study.

Dosage Adjustment Guideline for Toxicities

All treatment cycles were repeated until disease progression, unacceptable toxicity, or patient refusal. If patients had a leukocyte count of less than $2,000/\mu\text{L}$, a neutrophil count of less than $1,000/\mu\text{L}$, a platelet count of less than $70 \times 10^3/\mu\text{L}$, or grade 3 or worse rash, the administration of anticancer agents was postponed. S-1 was temporarily halted both in S-1 and in GS groups if patients had a creatinine level of 1.5 mg/dL or higher or grade 2 or worse diarrhea or stomatitis. Treatment was discontinued if these events did not resolve within 4 weeks after treatment suspension. In patients who experienced febrile neutropenia, grade 4 leukopenia, neutropenia, or thrombocytopenia or grade 3 or worse rash, the dose of gemcitabine was reduced by 200 mg/m^2 . In patients with febrile neutropenia; grade 4